Global Androgen Receptor Antagonist Market Growth 2025-2031
Description
The global Androgen Receptor Antagonist market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Androgen receptor (AR) is an important target of prostate cancer drugs, and its structure plays an important guiding role in drug development. The androgen receptor consists of 4 structural domains and 8 exons, which are N-terminal binding domain (NTD, exon 1), DNA binding domain (DBD, exon 2-3), hinge region ( HR, exon 4), C-terminal binding domain (LBD, exons 5-8), nuclear localization signal (NLS) is a dichotomous motif contained within exons 3 and 4. The LBD contains a buried hormone-binding pocket (HBP) and a transcriptional activation domain, AF2. AF2 plays an important role in the formation of homodimers, AF2 contains helices 3, 4, 5 and 12 (H3, H4, H5, H12), H12 can change position when ligand binds, when ligand binds to the binding pocket Upon binding, H12 folds back closer to the binding site, preventing ligand disengagement. Non-steroidal AR antagonists avoid the common hormone-like toxic side effects of steroidal AR antagonists, expand clinical applications, and are currently the most commonly used prostate cancer drugs in the United States.
United States market for Androgen Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Androgen Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Androgen Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Androgen Receptor Antagonist players cover Merck & Co., Inc, Sanofi, Astellas Pharma Inc, Pfizer, Johnson & Johnson, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Androgen Receptor Antagonist Industry Forecast” looks at past sales and reviews total world Androgen Receptor Antagonist sales in 2024, providing a comprehensive analysis by region and market sector of projected Androgen Receptor Antagonist sales for 2025 through 2031. With Androgen Receptor Antagonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Androgen Receptor Antagonist industry.
This Insight Report provides a comprehensive analysis of the global Androgen Receptor Antagonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Androgen Receptor Antagonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Androgen Receptor Antagonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Androgen Receptor Antagonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Androgen Receptor Antagonist.
This report presents a comprehensive overview, market shares, and growth opportunities of Androgen Receptor Antagonist market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
First Generation Inhibitors
Second Generation Inhibitors
Segmentation by Application:
Prostate Cancer
Breast Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck & Co., Inc
Sanofi
Astellas Pharma Inc
Pfizer
Johnson & Johnson
Bayer
Hinova
Jiangsu Hengrui Pharmaceuticals Co., Ltd
Kintor Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Androgen Receptor Antagonist market?
What factors are driving Androgen Receptor Antagonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Androgen Receptor Antagonist market opportunities vary by end market size?
How does Androgen Receptor Antagonist break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Androgen receptor (AR) is an important target of prostate cancer drugs, and its structure plays an important guiding role in drug development. The androgen receptor consists of 4 structural domains and 8 exons, which are N-terminal binding domain (NTD, exon 1), DNA binding domain (DBD, exon 2-3), hinge region ( HR, exon 4), C-terminal binding domain (LBD, exons 5-8), nuclear localization signal (NLS) is a dichotomous motif contained within exons 3 and 4. The LBD contains a buried hormone-binding pocket (HBP) and a transcriptional activation domain, AF2. AF2 plays an important role in the formation of homodimers, AF2 contains helices 3, 4, 5 and 12 (H3, H4, H5, H12), H12 can change position when ligand binds, when ligand binds to the binding pocket Upon binding, H12 folds back closer to the binding site, preventing ligand disengagement. Non-steroidal AR antagonists avoid the common hormone-like toxic side effects of steroidal AR antagonists, expand clinical applications, and are currently the most commonly used prostate cancer drugs in the United States.
United States market for Androgen Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Androgen Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Androgen Receptor Antagonist is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Androgen Receptor Antagonist players cover Merck & Co., Inc, Sanofi, Astellas Pharma Inc, Pfizer, Johnson & Johnson, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Androgen Receptor Antagonist Industry Forecast” looks at past sales and reviews total world Androgen Receptor Antagonist sales in 2024, providing a comprehensive analysis by region and market sector of projected Androgen Receptor Antagonist sales for 2025 through 2031. With Androgen Receptor Antagonist sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Androgen Receptor Antagonist industry.
This Insight Report provides a comprehensive analysis of the global Androgen Receptor Antagonist landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Androgen Receptor Antagonist portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Androgen Receptor Antagonist market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Androgen Receptor Antagonist and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Androgen Receptor Antagonist.
This report presents a comprehensive overview, market shares, and growth opportunities of Androgen Receptor Antagonist market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
First Generation Inhibitors
Second Generation Inhibitors
Segmentation by Application:
Prostate Cancer
Breast Cancer
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck & Co., Inc
Sanofi
Astellas Pharma Inc
Pfizer
Johnson & Johnson
Bayer
Hinova
Jiangsu Hengrui Pharmaceuticals Co., Ltd
Kintor Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Androgen Receptor Antagonist market?
What factors are driving Androgen Receptor Antagonist market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Androgen Receptor Antagonist market opportunities vary by end market size?
How does Androgen Receptor Antagonist break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
96 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Androgen Receptor Antagonist by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Androgen Receptor Antagonist by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
